Małyszczak, Krzysztof, Inglot, Małgorzata, Pawłowski, Tomasz et al. · Psychiatria polska · 2006
Interferon alpha, a medication used to treat hepatitis C and B, cancer, and other serious illnesses, commonly causes psychiatric and neurological side effects including depression, fatigue, anxiety, and cognitive problems in up to half of patients. These symptoms occur because interferon directly affects the brain and triggers a cascade of chemical changes, including alterations to serotonin and other neurotransmitters. The good news is that these symptoms can often be managed with antidepressants, therapy, and behavioral support.
This study is relevant to ME/CFS research because it details molecular mechanisms—particularly tryptophan depletion, kynurenine pathway activation, HPA axis dysregulation, and altered neurotransmitter function—that are also hypothesized to occur in ME/CFS. Understanding how interferon-induced illness produces fatigue, cognitive dysfunction, and mood disturbance in otherwise healthy patients provides a mechanistic model that may illuminate similar pathways in ME/CFS and guide treatment strategies.
This review does not prove that ME/CFS is caused by interferon or that all ME/CFS patients have interferon-like immune dysregulation. It also does not establish causality from correlation—neuropsychiatric symptoms may be multifactorial. The study does not directly compare interferon-induced illness to ME/CFS or examine whether ME/CFS patients show identical molecular abnormalities.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →